发布求助
文献互助 智能选刊 最新文献

Mental Health Clinician最新文献

筛选
英文 中文
Melatonin agonists in the management of sleep disorders: A focus on ramelteon and tasimelteon 褪黑激素激动剂在睡眠障碍治疗中的作用:聚焦于拉美替恩和塔美替恩
Mental Health Clinician Pub Date : 2014-12-23 DOI: 10.9740/MHC.N190087
Katie S. Adams, Ericka L. Crouse
{"title":"Melatonin agonists in the management of sleep disorders: A focus on ramelteon and tasimelteon","authors":"Katie S. Adams, Ericka L. Crouse","doi":"10.9740/MHC.N190087","DOIUrl":"https://doi.org/10.9740/MHC.N190087","url":null,"abstract":"Melatonin agonists have become an area of interest in the treatment of sleep disorders. This article reviews the available data on this class of medications, with a focus on ramelteon and tasimelteon.","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"1 1","pages":"59-64"},"PeriodicalIF":0.0,"publicationDate":"2014-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84741315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Use of second generation antipsychotics for treatment-resistant major depressive disorder 使用第二代抗精神病药物治疗难治性重度抑郁症
Mental Health Clinician Pub Date : 2014-12-23 DOI: 10.9740/MHC.N207192
R. Waite
{"title":"Use of second generation antipsychotics for treatment-resistant major depressive disorder","authors":"R. Waite","doi":"10.9740/MHC.N207192","DOIUrl":"https://doi.org/10.9740/MHC.N207192","url":null,"abstract":"Many of the second generation antipsychotics (SGAs) have been studied as adjunctive agents in the management of treatment-resistant major depressive disorder. Two have also been examined for use as monotherapy for depression. Currently, aripiprazole, olanzapine (in combination with fluoxetine), and quetiapine XR are approved by the FDA for use as adjunctive agents in the treatment of major depressive disorder, and no SGAs are FDA-approved as monotherapy for the disorder. This article reviews the available evidence regarding the use of SGAs in patients with treatment-resistant major depressive disorder and the subsequent role for these agents based on this evidence. There is evidence that aripiprazole, quetiapine, olanzapine, and risperidone can be effective in improving depressive symptoms when added to antidepressant therapy, but the benefits have to be weighed against their risk of producing serious adverse effects.","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"3 1","pages":"246-256"},"PeriodicalIF":0.0,"publicationDate":"2014-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89810465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Review of antidepressants in the treatment of behavioral and psychiatric symptoms in dementia (BPSD) 抗抑郁药物治疗痴呆(BPSD)行为和精神症状的研究进展
Mental Health Clinician Pub Date : 2014-12-23 DOI: 10.9740/MHC.N204508
Whitney M. Buterbaugh, Todd Jamrose, J. Lazzara, L. Honaker, Christopher J Thomas
{"title":"Review of antidepressants in the treatment of behavioral and psychiatric symptoms in dementia (BPSD)","authors":"Whitney M. Buterbaugh, Todd Jamrose, J. Lazzara, L. Honaker, Christopher J Thomas","doi":"10.9740/MHC.N204508","DOIUrl":"https://doi.org/10.9740/MHC.N204508","url":null,"abstract":"Behavioral disturbances are commonplace among patients with dementia. Management of these symptoms has proved difficult.1,2 Currently, there are no FDA approved pharmacologic treatments for the treatment of BPSD.3 Traditionally, atypical antipsychotics have been used to treat behavioral disturbances despite modest efficacy and undesirable adverse effects.3,4,5 Because of the increase in mortality, there is a continued push to reduce antipsychotic utilization in this population.9,10 Thus, many clinicians are using alternative agents such as antidepressants and mood stabilizers to help treat BPSD, while avoiding using antipsychotics. The goal of this review is to review, analyze, and discuss the current literature available on the use of antidepressants to treat BPSD.","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"14 1","pages":"183-188"},"PeriodicalIF":0.0,"publicationDate":"2014-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90367123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Adderall XR® and Vyvanse™
Mental Health Clinician Pub Date : 2014-12-23 DOI: 10.9740/MHC.N186948
Shari N. Allen
{"title":"Adderall XR® and Vyvanse™","authors":"Shari N. Allen","doi":"10.9740/MHC.N186948","DOIUrl":"https://doi.org/10.9740/MHC.N186948","url":null,"abstract":"Adderall XR® (MAS XR) and Vyvanse™ (LDX) are both schedule II amphetamine-based central nervous system stimulants indicated for the treatment of attention-deficit/hyperactivity disorder. Differences among the two primarily involve dosage form, pharmacokinetic profiles, and abuse potential. MAS XR and LDX are both long-acting stimulants with an approximate duration of action of 10 hours. The long-acting property of LDX is secondary to its prodrug formulation, whereas MAS XR utilizes bead filled capsules that mimic twice daily dosing upon administration. MAS XR is a substrate of CYP 2D6 while LDX does not utilize the cytochrome P450 enzymes for metabolism. There are few efficacy studies that directly compare LDX and MAS XR. There are no head to head abuse liability studies for MAS XR and LDX; however, the prodrug formulation of LDX is proposed to have lower abuse potential.","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"44 1","pages":"8-10"},"PeriodicalIF":0.0,"publicationDate":"2014-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74957492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment and management of chronic pain in patients with depression and anxiety 抑郁和焦虑患者慢性疼痛的评估和处理
Mental Health Clinician Pub Date : 2014-12-23 DOI: 10.9740/MHC.N198935
Charity Hoffelt, Andrew Zwack
{"title":"Assessment and management of chronic pain in patients with depression and anxiety","authors":"Charity Hoffelt, Andrew Zwack","doi":"10.9740/MHC.N198935","DOIUrl":"https://doi.org/10.9740/MHC.N198935","url":null,"abstract":"This article will review the role of the pharmacist in the management of chronic pain in patients with comorbid mood disorders.","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"73 1","pages":"146-152"},"PeriodicalIF":0.0,"publicationDate":"2014-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73911195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Psychotropic-induced sexual dysfunction 精神药物引起的性功能障碍
Mental Health Clinician Pub Date : 2014-12-23 DOI: 10.9740/MHC.N197919
E. Borg, Benjamin Chavez
{"title":"Psychotropic-induced sexual dysfunction","authors":"E. Borg, Benjamin Chavez","doi":"10.9740/MHC.N197919","DOIUrl":"https://doi.org/10.9740/MHC.N197919","url":null,"abstract":"Psychotropic-induced sexual dysfunction is a common and bothersome side effect of psychotropic medications. The majority of information available on the subject primarily pertains to antidepressants, but antipsychotics can also cause significant sexual dysfunction. The mechanisms behind these adverse events are thought to be primarily due to antidepressants' effects on serotonin and to antipsychotics' anti-dopaminergic activity. Sexual dysfunction can have many causes, not just psychotropic medication, therefore this article aims to examine the etiology of sexual dysfunction, as well as discuss differential diagnoses. Treatment for psychotropic-induced sexual dysfunction will be discussed, with more data available for the treatment of antidepressant-induced sexual dysfunction. The paucity of data for antipsychotic-induced sexual dysfunction does make it more difficult to treat.","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"31 1","pages":"138-145"},"PeriodicalIF":0.0,"publicationDate":"2014-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79723618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Clonidine and guanfacine IR vs ER: Old drugs with “new” formulations 可乐定和胍法辛IR vs ER:有“新”配方的老药
Mental Health Clinician Pub Date : 2014-12-23 DOI: 10.9740/MHC.N186955
Lyndsay Gormley, A. Turner, Kathryn N Freeland
{"title":"Clonidine and guanfacine IR vs ER: Old drugs with “new” formulations","authors":"Lyndsay Gormley, A. Turner, Kathryn N Freeland","doi":"10.9740/MHC.N186955","DOIUrl":"https://doi.org/10.9740/MHC.N186955","url":null,"abstract":"After a long history of use for hypertension, clonidine and guanfacine have re-emerged on the market as treatment options for attention-deficit/hyperactivity disorder, particularly in patients who are unable to tolerate or need an alternative to stimulant medications as well as those who have residual symptoms despite adequate therapy with stimulants. In recent years, new formulations of long-acting clonidine and guanfacine have come to market. The purpose of this article is to review the pharmacokinetic properties and clinical utility of these new agents while comparing the medications and parent compounds in terms of dosing, adverse effects, and costs of treatment.","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"13 1","pages":"22-26"},"PeriodicalIF":0.0,"publicationDate":"2014-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89093106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Treatment options for sundowning in patients with dementia 痴呆患者日落的治疗选择
Mental Health Clinician Pub Date : 2014-12-23 DOI: 10.9740/MHC.N204525
Joseph Blais, M. Zolezzi, C. Sadowski
{"title":"Treatment options for sundowning in patients with dementia","authors":"Joseph Blais, M. Zolezzi, C. Sadowski","doi":"10.9740/MHC.N204525","DOIUrl":"https://doi.org/10.9740/MHC.N204525","url":null,"abstract":"Objective. To review the evidence for the pharmacologic and non-pharmacologic management of sundowning in patients with dementia. Methods. Databases were searched using the terms sundown, circadian, chronobiological, biological clock, elderly, aged, geriatric, and senior. Studies selected for inclusion assessed potential interventions for the treatment of sundowning or nocturnal agitation. Results. A total of thirteen individual studies and two systematic reviews were evaluated. Study design and outcomes varied, but many measured sleep and nocturnal agitation. Non-pharmacologic interventions that may be of benefit include bright light therapy, music therapy, and aromatherapy. Pharmacologic therapies generally provided minimal benefit and were associated with safety concerns. Supportive evidence was found for the use of melatonin and antipsychotics. Evidence for antidepressants, donepezil, and dronabinol was weaker. Supportive evidence for the use of benzodiazepines was not found and thus cannot be recomme...","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"27 1","pages":"189-195"},"PeriodicalIF":0.0,"publicationDate":"2014-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77106452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Toolbox: Management of behavioral and psychological symptoms of dementia 工具箱:痴呆症的行为和心理症状的管理
Mental Health Clinician Pub Date : 2014-12-23 DOI: 10.9740/MHC.N204535
Joshana K Goga
{"title":"Toolbox: Management of behavioral and psychological symptoms of dementia","authors":"Joshana K Goga","doi":"10.9740/MHC.N204535","DOIUrl":"https://doi.org/10.9740/MHC.N204535","url":null,"abstract":"While antipsychotics have been used to treat psychosis or aggressive behaviors in dementia populations, they appear to have a high side effect profile that leads to high discontinuation rates. Additionally, antipsychotics, as a class, carry a black box warning for use in the dementia population. Both CMS and APA have announced initiatives over the past two years to reduce the inappropriate prescribing of antipsychotics in order to manage BPSD. Mood stabilizers may be considered as an alternative to neuroleptics. This table presents data on the efficacy of mood stabilizing drugs for the management of BPSD.","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"38 1","pages":"164-165"},"PeriodicalIF":0.0,"publicationDate":"2014-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79964064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Levomilnacipran (Fetzima™) for the treatment of major depressive disorder 左旋美那西普兰(Fetzima™)用于治疗重度抑郁症
Mental Health Clinician Pub Date : 2014-12-23 DOI: 10.9740/MHC.N186963
C. Ross
{"title":"Levomilnacipran (Fetzima™) for the treatment of major depressive disorder","authors":"C. Ross","doi":"10.9740/MHC.N186963","DOIUrl":"https://doi.org/10.9740/MHC.N186963","url":null,"abstract":"Levomilnacipran (Fetzima™) was approved by the United States Food and Drug Administration (FDA) in July 2013 for the treatment of Major Depressive Disorder (MDD) in adults. Levomilnacipran is the (1S,2R) enantiomer of racemic milnacipran and represents one of the newest medications designed and marketed as an enantiomer of an already approved medication with hopes of improving efficacy and limiting side effects. This article reviews the evidence supporting the use of milnacipran for MDD, examines the clinical studies behind levomilnacipran's approval, and discusses practical considerations regarding the use of this new antidepressant medication.","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"60 1","pages":"27-30"},"PeriodicalIF":0.0,"publicationDate":"2014-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80626150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信